Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Stock Climbs 6.6 Percent After Positive Q3 Results

NEW YORK, Oct. 25 (GenomeWeb News) - Shares in Illumina were up 6.6 percent, or $.89, at $14.49 in mid-afternoon trading after the company announced positive third-quarter results yesterday.

 

As GenomeWeb News reported yesterday, Illumina had a 44-percent increase in third-quarter revenues and narrowed its quarterly net loss to $1.4 million from $2 million from a year ago. Illumina credited the increase in revenue to a "record" number of BeadStations shipped during the quarter.

 

Today, Illumina said it has sold a BeadStation system to PharmacoDesign that gives Illumina exclusive, licensed access to biomarkers discovered through disease studies.

 

Separately today, Illumina has asked the US Patent and Trademark Office to investigate the validity of a patent currently owned by Affymetrix that Illumina claims its scientists had originally invented.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.